Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

ClinicalTrials.gov ID: NCT02153632

Public ClinicalTrials.gov record NCT02153632. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Study identification

NCT ID
NCT02153632
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Enrollment
135 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • amantadine HCl ER Drug

Drug

Eligibility (public fields only)

Age range
30 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 29, 2014
Primary completion
May 19, 2016
Completion
May 19, 2016
Last update posted
Feb 15, 2022

2014 – 2016

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
24
Facility City State ZIP Site status
Not listed Tucson Arizona 85724
Not listed Fountain Valley California 92708
Not listed Irvine California 92602
Not listed Pasadena California 91105
Not listed Ventura California 93001
Not listed Boulder Colorado 80304
Not listed Hollywood Florida 33021
Not listed Miami Florida 40502
Not listed North Palm Beach Florida 33404
Not listed Sarasota Florida 34243
Not listed Tampa Florida 33612
Not listed Chicago Illinois 60612
Not listed Indianapolis Indiana 46202
Not listed Lexington Kentucky 40502
Not listed Baton Rouge Louisiana 70810
Not listed Ann Arbor Michigan 48103
Not listed Summit New Jersey 07901
Not listed Brooklyn New York 11215
Not listed Patchogue New York 11772
Not listed Raleigh North Carolina 27612
Not listed Columbus Ohio 43004
Not listed Round Rock Texas 78681
Not listed Orem Utah 84058
Not listed Kirkland Washington 98033

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02153632, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 15, 2022 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02153632 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →